CareDx (CDNA) Given Daily Media Impact Rating of 0.14

Media coverage about CareDx (NASDAQ:CDNA) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6484963533906 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of CareDx (NASDAQ CDNA) traded up $0.14 during mid-day trading on Monday, hitting $7.24. The stock had a trading volume of 180,600 shares, compared to its average volume of 192,775. CareDx has a one year low of $0.76 and a one year high of $7.98. The firm has a market cap of $207.09, a PE ratio of -4.00 and a beta of 1.05. The company has a current ratio of 0.55, a quick ratio of 0.35 and a debt-to-equity ratio of -124.53.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.02. CareDx had a negative return on equity of 157.00% and a negative net margin of 84.14%. The company had revenue of $12.19 million for the quarter, compared to analysts’ expectations of $12.05 million. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. sell-side analysts predict that CareDx will post -0.83 EPS for the current year.

CDNA has been the topic of several analyst reports. Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. Craig Hallum restated a “buy” rating and issued a $10.00 target price (up from $4.00) on shares of CareDx in a research report on Monday, October 9th. Raymond James Financial upgraded CareDx from a “market perform” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Wednesday, September 27th. ValuEngine upgraded CareDx from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $7.00 target price (up from $3.00) on shares of CareDx in a research report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. CareDx has a consensus rating of “Buy” and an average price target of $7.75.

In other news, COO Mitchell J. Nelles sold 10,948 shares of CareDx stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $7.17, for a total transaction of $78,497.16. Following the transaction, the chief operating officer now directly owns 84,225 shares in the company, valued at approximately $603,893.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider James P. Yee sold 29,197 shares of CareDx stock in a transaction on Friday, December 8th. The shares were sold at an average price of $7.00, for a total value of $204,379.00. Following the transaction, the insider now owns 74,795 shares in the company, valued at $523,565. The disclosure for this sale can be found here. 5.40% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “CareDx (CDNA) Given Daily Media Impact Rating of 0.14” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2018/01/08/caredx-cdna-given-daily-media-impact-rating-of-0-14.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

What are top analysts saying about CareDx? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CareDx and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit